Sidney Kennedy


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.

Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT).

He has published more than 350 peer reviewed publications and 11 books on depression and related topics.

Recent Publications

  1. Baskaran, A, Farzan, F, Milev, R, Brenner, CA, Alturi, S, Pat McAndrews, M et al.. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. J Affect Disord. 2017;227 :542-549. doi: 10.1016/j.jad.2017.10.028. PubMed PMID:29169123 .
  2. Fonseka, TM, MacQueen, GM, Kennedy, SH. Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. J Affect Disord. 2017; :. doi: 10.1016/j.jad.2017.10.049. PubMed PMID:29150145 .
  3. Feffer, K, Lee, HH, Mansouri, F, Giacobbe, P, Vila-Rodriguez, F, Kennedy, SH et al.. Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. Brain Stimul. 2017; :. doi: 10.1016/j.brs.2017.10.010. PubMed PMID:29107623 .
  4. Giacobbe, P, Rakita, U, Lam, R, Milev, R, Kennedy, SH, McIntyre, RS et al.. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. J Affect Disord. 2018;226 :294-300. doi: 10.1016/j.jad.2017.09.041. PubMed PMID:29028590 .
  5. Dodd, S, Mitchell, PB, Bauer, M, Yatham, L, Young, AH, Kennedy, SH et al.. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World J. Biol. Psychiatry. 2017; :1-19. doi: 10.1080/15622975.2017.1379609. PubMed PMID:28984491 .
  6. Kennedy, SH, Klumpp, DA. Michael Additions Involving Amino Acid Esters with Alkenyl N-Heterocycles. J. Org. Chem. 2017;82 (19):10219-10225. doi: 10.1021/acs.joc.7b01724. PubMed PMID:28846408 .
  7. Allega, OR, Leng, X, Vaccarino, A, Skelly, M, Lanzini, M, Hidalgo, MP et al.. Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. J Affect Disord. 2018;225 :54-63. doi: 10.1016/j.jad.2017.07.047. PubMed PMID:28787704 .
  8. Farzan, F, Atluri, S, Frehlich, M, Dhami, P, Kleffner, K, Price, R et al.. Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Sci Rep. 2017;7 (1):7473. doi: 10.1038/s41598-017-07613-x. PubMed PMID:28785082 PubMed Central PMC5547036.
  9. Maciukiewicz, M, Marshe, VS, Tiwari, AK, Fonseka, TM, Freeman, N, Kennedy, JL et al.. Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics J. 2017; :. doi: 10.1038/tpj.2017.29. PubMed PMID:28696415 .
  10. Bhat, V, Kennedy, SH. Recognition and management of antidepressant discontinuation syndrome. J Psychiatry Neurosci. 2017;42 (4):E7-E8. . PubMed PMID:28639936 PubMed Central PMC5487275.
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Mental Health, St. Michael’s Hospital
  • Professor, Department of Psychiatry, University of Toronto
  • Research Scientist, Krembil Neurosciences, University Health Network